QUESTIONS| Event Date/Time: May 26, 2011 |
Report as SpamDescription
To address the continuing advances in disease therapies, as well as solving unmet needs of ocular disease drug therapies in aging individuals, GTCbio is proud to announce its 3rd Ocular Diseases & Drug Discovery Conference.
Several companies have taken the initiative in developing ocular disease therapies, with exciting new developments in kinase inhibitors. These companies include Pfizer, EyeGate, pSivida, Merck, Regeneron, Genzyme, Novartis, Ophthotech, Macusight, Neurotech, GlaxoSmithKline and many more.
To help promote the discovery of ocular disease and drug development, GTCbio is bringing together leading scientists, researchers, and experts to discuss and collaborate on the latest research and drugs available in combating and curing age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, uveitis and other eye diseases at the 3rd Ocular Diseases & Drug Discovery Conference.
Several companies have taken the initiative in developing ocular disease therapies, with exciting new developments in kinase inhibitors. These companies include Pfizer, EyeGate, pSivida, Merck, Regeneron, Genzyme, Novartis, Ophthotech, Macusight, Neurotech, GlaxoSmithKline and many more.
To help promote the discovery of ocular disease and drug development, GTCbio is bringing together leading scientists, researchers, and experts to discuss and collaborate on the latest research and drugs available in combating and curing age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, uveitis and other eye diseases at the 3rd Ocular Diseases & Drug Discovery Conference.
